1. Home
  2. IQMX vs AGIO Comparison

IQMX vs AGIO Comparison

Compare IQMX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IQMX

IQM Quantum Computers Oyj American Depositary Shares

N/A

Current Price

$9.84

Market Cap

2.6B

Sector

N/A

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$30.34

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQMX
AGIO
Founded
N/A
2007
Country
Finland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
IQMX
AGIO
Price
$9.84
$30.34
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$38.88
AVG Volume (30 Days)
506.5K
1.1M
Earning Date
N/A
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$76.75
Revenue Next Year
N/A
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.14
$22.24
52 Week High
$15.10
$46.00

Technical Indicators

Market Signals
Indicator
IQMX
AGIO
Relative Strength Index (RSI) 29.66 33.83
Support Level N/A $26.71
Resistance Level $11.95 $36.07
Average True Range (ATR) 0.70 1.89
MACD -0.08 -1.07
Stochastic Oscillator 0.31 24.50

Price Performance

Historical Comparison
IQMX
AGIO

About IQMX IQM Quantum Computers Oyj American Depositary Shares

IQM Quantum Computers Oyj is engaged in superconducting quantum computing and provides quantum computing systems and cloud platform access to enterprises, research institutions, high-performance computing centers, and national laboratories. Its offerings include quantum systems based on an open and modular architecture. The company has operations in Munich, Germany, and deployments across Europe, Asia, and North America.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: